tranexamic acid has been researched along with Aqueductal Stenosis in 7 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, Cyklokapron; AB Kabi, Stockholm, Sweden) in the prevention of early rebleeding after the rupture of an intracranial aneurysm." | 9.05 | Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. ( Fodstad, H; Forssell, A; Liliequist, B; Schannong, M, 1981) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 9.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 7.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
| "One hundred patients with a verified subarachnoid haemorrhage were studied in a double blind, placebo-controlled trial at a single centre to determine the value and relative risks of tranexamic acid (TXA) in the management of ruptured intracranial aneurysms." | 5.06 | Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. ( Hitchcock, ER; Meyer, CH; Tsementzis, SA, 1990) |
| "A randomized controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, Cyklokapron; AB Kabi, Stockholm, Sweden) in the prevention of early rebleeding after the rupture of an intracranial aneurysm." | 5.05 | Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. ( Fodstad, H; Forssell, A; Liliequist, B; Schannong, M, 1981) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 5.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "Among our patients with ruptured intracranial aneurysms 149 were managed pre-operatively with a combination of tranexamic acid (AMCA), 3 gm daily, and aprotinin at an average of 400,000 KIU (Kallikrein inactivating units) daily." | 3.67 | Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. ( Guidetti, B; Pastore, FS; Rizzo, A; Spallone, A, 1987) |
| "Cerebral ischemia was treated with vigorous plasma volume expansion under intermittent monitoring of pulmonary wedge pressure, cardiac output, and arterial blood pressure, aiming for a hematocrit of 0." | 1.30 | Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. ( Avezaat, CJ; Bijvoet, HW; Hasan, D; Vermeij, FH, 1998) |
| "An aneurysm-induced hydrocephalus was observed in two series of patients who were treated antifibrinolytically in different ways: A = 3 g/day of AMCA + 3 - 400,000 KIU/day of aprotinins, B = 6 g/day of AMCA." | 1.27 | Hydrocephalus following aneurysmal SAH. ( Gagliardi, FM; Spallone, A, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Xiong, Y | 1 |
| Guo, X | 1 |
| Huang, X | 1 |
| Kang, X | 1 |
| Zhou, J | 1 |
| Chen, C | 1 |
| Pan, Z | 1 |
| Wang, L | 1 |
| Goldbrunner, R | 1 |
| Stavrinou, L | 1 |
| Stavrinou, P | 1 |
| Lin, S | 1 |
| Chen, Y | 1 |
| Hu, W | 1 |
| Zheng, F | 1 |
| Spallone, A | 2 |
| Gagliardi, FM | 1 |
| Fodstad, H | 2 |
| Forssell, A | 1 |
| Liliequist, B | 2 |
| Schannong, M | 2 |
| Vermeij, FH | 1 |
| Hasan, D | 1 |
| Bijvoet, HW | 1 |
| Avezaat, CJ | 1 |
| Thulin, CA | 1 |
| Tsementzis, SA | 1 |
| Hitchcock, ER | 1 |
| Meyer, CH | 1 |
| Pastore, FS | 1 |
| Rizzo, A | 1 |
| Guidetti, B | 1 |
1 review available for tranexamic acid and Aqueductal Stenosis
| Article | Year |
|---|---|
Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Humans; Hydrocephalus; Quality of Life; Subarach | 2023 |
3 trials available for tranexamic acid and Aqueductal Stenosis
| Article | Year |
|---|---|
Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial.
Topics: Adult; Aged; Brain Ischemia; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Female; Humans; | 1981 |
Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.
Topics: Adult; Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Constriction, Pathologic; Cyclohexan | 1978 |
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.
Topics: Adult; Aged; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials as Topic; Cyclohexanecarbo | 1990 |
3 other studies available for tranexamic acid and Aqueductal Stenosis
| Article | Year |
|---|---|
Hydrocephalus following aneurysmal SAH.
Topics: Apoproteins; Drug Therapy, Combination; Humans; Hydrocephalus; Intracranial Aneurysm; Intracranial P | 1983 |
Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Female; Hemorrhage; Humans; Hydrocephalus; Int | 1998 |
Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms.
Topics: Adult; Aprotinin; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Dose-Response Relationship | 1987 |